La Unión Europea ha aprobado el uso de ‘Galvus’ (vildagliptina), de Novartis, para diabéticos tipo 2 con insuficiencia renal moderada o grave y limitadas opciones terapéuticas. Estas complicaciones afectan al 25% de estos pacientes en la actualidad y supone una causa importante de mortalidad. Más
- Long-Acting Injectable ART in Practice: A Mixed Methods Implementation Study Assessing the Feasibility of Using LAI ART in High Risk Populations and At Alternative Low Barrier Care Sites 24/04/2024
- A Machine Learning Model for Identifying Sexual Health Influencers to Promote the Secondary Distribution of HIV Self-Testing Among Gay, Bisexual, and Other Men Who Have Sex With Men in China: Quasi-Experimental Study 24/04/2024
- Participant perspectives on incentives for TB preventative therapy adherence and reduced alcohol use: A qualitative study 24/04/2024
- Improving patient-centred counselling skills among lay healthcare workers in South Africa using the Thusa-Thuso motivational interviewing training and support program 24/04/2024
- An Integrated mHealth App for Smoking Cessation in Black Smokers With HIV: Protocol for a Randomized Controlled Trial 24/04/2024
 |
 |
 |
 |
- Solving the riddle of the sphingolipids in coronary artery disease 24/04/2024
- Tumor cells evade the immune system early on: Newly discovered mechanism could significantly improve cancer immunotherapies 24/04/2024
- Social media can be used to increase fruit and vegetable intake in young people 24/04/2024
- Low intensity exercise linked to reduced depression 24/04/2024
- Positive effect of midazolam after cardiac arrest 24/04/2024
 |
24 de abril de 2024
| Sitio presentado el 18 de mayo de 2010 |  |
DE NUESTROS LECTORES